Compare Ascendis Pharma A/S (ASND) vs Zscaler Inc (ZS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Zscaler Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Zscaler Inc trades at $139.95 (market cap $22.52B). The key difference: Zscaler Inc is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| ASND | ZS | |
|---|---|---|
Market Cap | $17.74B | $22.52B |
Sector | Health | Technology |
52-Week High | $277.18 | $336.27 |
52-Week Low | $163.32 | $118.05 |
Enterprise Value | $18.11B | $20.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Zscaler (ZS) trades at $139.27, down 5.34% on the day, amid mixed signals. The stock shows strong revenue growth with 2025 revenue reaching $2.67 billion and consistent quarterly EPS beats, but remains unprofitable with a net income margin of -2.44%. Technical indicators are bullish on moving averages but show overbought RSI levels. Recent news highlights class action investigations and AI infrastructure cost pressures, yet analyst sentiment remains overwhelmingly positive with a consensus price target of $192.64.
The outlook for ZS is cautiously optimistic driven by robust cybersecurity demand and AI security traction, but risks include profitability challenges, rising costs, and legal scrutiny. Wall Street maintains a strong buy consensus (79% buy ratings), suggesting significant upside potential if execution improves and margins stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
